Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20518838rdf:typepubmed:Citationlld:pubmed
pubmed-article:20518838lifeskim:mentionsumls-concept:C0032659lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C1556095lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C0042900lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C0076930lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C0919538lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:20518838lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:20518838pubmed:issue4lld:pubmed
pubmed-article:20518838pubmed:dateCreated2010-7-19lld:pubmed
pubmed-article:20518838pubmed:abstractTextThe precise cause of vitiligo is unknown. However, autoimmunity is considered the most likely aetiology, especially in nonsegmental vitiligo (NSV). In this study we determined whether or not the transforming growth factor beta receptor II (TGFBR2) gene contributes to susceptibility for NSV in the Korean population. Blood samples were collected from 415 controls and 233 cases. We selected three single nucleotide polymorphisms (SNPs) in the TGFBR2 gene. The genotypes of the SNPs were determined using direct sequencing. All of the SNPs were significantly different between the vitiligo patients and controls (rs2005061, co-dominant, dominant, recessive, P < 0.05; rs3773645, co-dominant, dominant, recessive, P < 0.05; rs3773649, co-dominant, recessive, P < 0.05). In addition, haplotype 1 (CG) and haplotype 2 (GA) of the linkage disequilibrium (LD) block were also associated with a risk of NSV. The present study suggests that TGFBR2 might be related to NSV.lld:pubmed
pubmed-article:20518838pubmed:languageenglld:pubmed
pubmed-article:20518838pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20518838pubmed:citationSubsetIMlld:pubmed
pubmed-article:20518838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20518838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20518838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20518838pubmed:statusMEDLINElld:pubmed
pubmed-article:20518838pubmed:monthAuglld:pubmed
pubmed-article:20518838pubmed:issn1744-313Xlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:EBYT MTMlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:PERM IMIlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:MEER ARAlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:YunJ YJYlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:LeeM-HMHlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:ChungJ-HJHlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:YimS-VSVlld:pubmed
pubmed-article:20518838pubmed:authorpubmed-author:ShinM-kMKlld:pubmed
pubmed-article:20518838pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20518838pubmed:volume37lld:pubmed
pubmed-article:20518838pubmed:ownerNLMlld:pubmed
pubmed-article:20518838pubmed:authorsCompleteYlld:pubmed
pubmed-article:20518838pubmed:pagination289-91lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:meshHeadingpubmed-meshheading:20518838...lld:pubmed
pubmed-article:20518838pubmed:year2010lld:pubmed
pubmed-article:20518838pubmed:articleTitleTransforming growth factor beta receptor II (TGFBR2) polymorphisms and the association with nonsegmental vitiligo in the Korean population.lld:pubmed
pubmed-article:20518838pubmed:affiliationDepartment of Clinical Pharmacology, School of Medicine, Kyung Hee University, Seoul, Korea.lld:pubmed
pubmed-article:20518838pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20518838pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:7048entrezgene:pubmedpubmed-article:20518838lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20518838lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20518838lld:entrezgene